A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growthin vivo
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growthin vivo
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 17, Issue 5, Pages 498-506
Publisher
Informa UK Limited
Online
2016-03-09
DOI
10.1080/15384047.2016.1156266
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Replacing antibodies with aptamers in lateral flow immunoassay
- (2015) Ailiang Chen et al. BIOSENSORS & BIOELECTRONICS
- Achieving successful delivery of oligonucleotides — From physico-chemical characterization to in vivo evaluation
- (2015) Anna Scomparin et al. BIOTECHNOLOGY ADVANCES
- Applications of nanoparticles for diagnosis and therapy of cancer
- (2015) S C Baetke et al. BRITISH JOURNAL OF RADIOLOGY
- Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
- (2015) Jagat Kanwar et al. CURRENT MEDICINAL CHEMISTRY
- Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells
- (2015) Jaroslaw Ruczynski et al. FOLIA HISTOCHEMICA ET CYTOBIOLOGICA
- In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer
- (2015) Anke Vanderstraeten et al. JOURNAL OF IMMUNOTHERAPY
- Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties
- (2015) Min Xiao et al. PLoS One
- Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer
- (2015) Marian Danilewicz et al. POLISH JOURNAL OF PATHOLOGY
- Survivin expression and serum levels in pancreatic cancer
- (2015) He Dong et al. World Journal of Surgical Oncology
- Aptamers as Drug Delivery Vehicles
- (2014) Sven Kruspe et al. ChemMedChem
- Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB–siRNA conjugates
- (2014) Trinna L. Cuellar et al. NUCLEIC ACIDS RESEARCH
- Brain-Targeted Delivery of Trans-Activating Transcriptor-Conjugated Magnetic PLGA/Lipid Nanoparticles
- (2014) Xiangru Wen et al. PLoS One
- Site-Specific Antibody–Polymer Conjugates for siRNA Delivery
- (2013) Hua Lu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Polymer–drug conjugates: Origins, progress to date and future directions
- (2012) Jindřich Kopeček ADVANCED DRUG DELIVERY REVIEWS
- Liposomal drug delivery systems: From concept to clinical applications
- (2012) Theresa M. Allen et al. ADVANCED DRUG DELIVERY REVIEWS
- Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
- (2011) X. Ni et al. CURRENT MEDICINAL CHEMISTRY
- Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex
- (2010) Eunjung Kim et al. BIOMATERIALS
- Efficient siRNA delivery by novel PTD-DRBD fusion proteins
- (2010) Akiko Eguchi et al. CELL CYCLE
- RNAi and small interfering RNAs in human disease therapeutic applications
- (2010) Monica R. Lares et al. TRENDS IN BIOTECHNOLOGY
- Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity
- (2009) J. Shen et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors
- (2009) Justin P Dassie et al. NATURE BIOTECHNOLOGY
- Efficient siRNA delivery into primary cells by a peptide transduction domain–dsRNA binding domain fusion protein
- (2009) Akiko Eguchi et al. NATURE BIOTECHNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More